GSK, J&J, and AZ head this year’s access to medicines ranking

The article moves on to the companies at the lower end of the Index, detailing some of the reasons for their ranking.

Evidence of progress is covered, such as the fact that all 20 companies in scope have, for the first time, reported an over-arching access-to-medicine strategy. The article also notes that 'on the flip side' there is still a long way to go, especially in relation to R&D for emerging tropical diseases.

Read the article on the pharmaphorum website.